Genetic determinants of uveal melanoma
- PMID: 22042019
- DOI: 10.1159/000328270
Genetic determinants of uveal melanoma
Abstract
Uveal melanoma (UM) arises from neural crest-derived melanocytes of the choroid and the ciliary body. About 50% of patients develop metastatic disease despite efficient control of the primary tumor. For about 15 years, cytogenetic and, recently, genome-wide analysis techniques have shown that UM can be classified into 2 genomic groups correlating with prognostic clinicopathologic features: class 1 tumors, with a low risk of metastases, typically characterized by a gain of the 6p chromosome arm, often associated with a gain of the distal part of the 8q chromosome arm, and class 2 tumors, with a high metastatic risk, presenting loss of the entire chromosome 3 and gain of the entire 8q, related to the formation of isochromosomes. Genome-wide expression profiling has proved to be a powerful tool for separating these 2 classes. However, despite advances in the genomic and prognostic characterization of UM, the knowledge of pathways deregulated in these tumors is just emerging and, in contrast to cutaneous melanoma, no major predisposing genes are known. Altered or deregulated genes are reviewed in this chapter. Inactivating mutations have recently been identified by exome sequencing in gene BAP1, mapping to 3p21.1, in class 2 tumors. Among other discriminant genes identified from genome-wide expression profiling, PTP4A3, mapping to 8q24.3, coding for a protein promoting cell migration, is highly overexpressed in class 2 tumors. The overall expression signature of class 2 tumors suggests they may originate from neuroectodermal stem cells.
Copyright © 2012 S. Karger AG, Basel.
Similar articles
-
Prognostic impact of chromosomal aberrations and GNAQ, GNA11 and BAP1 mutations in uveal melanoma.Acta Ophthalmol. 2018 Feb;96(1):31-38. doi: 10.1111/aos.13452. Epub 2017 Apr 26. Acta Ophthalmol. 2018. PMID: 28444874
-
PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.JAMA Ophthalmol. 2017 Jun 1;135(6):541-549. doi: 10.1001/jamaophthalmol.2017.0729. JAMA Ophthalmol. 2017. PMID: 28448663 Free PMC article.
-
Relationship between clinical features, GEP class, and PRAME expression in uveal melanoma.Graefes Arch Clin Exp Ophthalmol. 2019 Jul;257(7):1541-1545. doi: 10.1007/s00417-019-04335-w. Epub 2019 May 7. Graefes Arch Clin Exp Ophthalmol. 2019. PMID: 31065847
-
Genetic prognostication in uveal melanoma.Acta Ophthalmol. 2018 Jun;96(4):331-347. doi: 10.1111/aos.13580. Epub 2017 Nov 4. Acta Ophthalmol. 2018. PMID: 29105334 Review.
-
Uveal melanoma: Towards a molecular understanding.Prog Retin Eye Res. 2020 Mar;75:100800. doi: 10.1016/j.preteyeres.2019.100800. Epub 2019 Sep 26. Prog Retin Eye Res. 2020. PMID: 31563544 Review.
Cited by
-
Proteomics of uveal melanoma: a minireview.J Oncol. 2013;2013:820953. doi: 10.1155/2013/820953. Epub 2013 Sep 3. J Oncol. 2013. PMID: 24078811 Free PMC article. Review.
-
Heterogeneity of monosomy 3 in fine needle aspiration biopsy of choroidal melanoma.Mol Vis. 2013 Sep 7;19:1892-900. eCollection 2013. Mol Vis. 2013. PMID: 24049435 Free PMC article.
-
Establishment of novel cell lines recapitulating the genetic landscape of uveal melanoma and preclinical validation of mTOR as a therapeutic target.Mol Oncol. 2014 Dec;8(8):1508-20. doi: 10.1016/j.molonc.2014.06.004. Epub 2014 Jun 13. Mol Oncol. 2014. PMID: 24994677 Free PMC article.
-
PleiotRHOpic: Rho pathways are essential for all stages of Neural Crest development.Small GTPases. 2014;5:e27975. doi: 10.4161/sgtp.27975. Epub 2014 Mar 10. Small GTPases. 2014. PMID: 24614304 Free PMC article. Review.
-
Heterogeneity revealed by integrated genomic analysis uncovers a molecular switch in malignant uveal melanoma.Oncotarget. 2015 Nov 10;6(35):37824-35. doi: 10.18632/oncotarget.5637. Oncotarget. 2015. PMID: 26462151 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical